These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 9888619)
1. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Greenberg BD; Benjamin J; Martin JD; Keuler D; Huang SJ; Altemus M; Murphy DL Psychopharmacology (Berl); 1998 Dec; 140(4):434-44. PubMed ID: 9888619 [TBL] [Abstract][Full Text] [Related]
2. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
3. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder. Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Zitterl W; Meszaros K; Hornik K; Twaroch T; Dossenbach M; Zitterl-Eglseer K; Zapotoczky HG Wien Klin Wochenschr; 1999 Jun; 111(11):439-42. PubMed ID: 10420495 [TBL] [Abstract][Full Text] [Related]
5. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Roca CA; Schmidt PJ; Smith MJ; Danaceau MA; Murphy DL; Rubinow DR Am J Psychiatry; 2002 Nov; 159(11):1876-81. PubMed ID: 12411222 [TBL] [Abstract][Full Text] [Related]
6. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679 [TBL] [Abstract][Full Text] [Related]
7. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220 [TBL] [Abstract][Full Text] [Related]
8. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder. Besiroglu L; Çetinkaya N; Selvi Y; Atli A Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243 [TBL] [Abstract][Full Text] [Related]
9. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131 [TBL] [Abstract][Full Text] [Related]
10. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder. Giasuddin NA; Nahar JS; Morshed NM; Balhara YP; Sobhan MA Pak J Pharm Sci; 2013 Jan; 26(1):95-8. PubMed ID: 23261733 [TBL] [Abstract][Full Text] [Related]
12. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158 [TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357 [TBL] [Abstract][Full Text] [Related]
14. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816 [TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Soltani F; Sayyah M; Feizy F; Malayeri A; Siahpoosh A; Motlagh I Hum Psychopharmacol; 2010 Aug; 25(6):509-13. PubMed ID: 20737524 [TBL] [Abstract][Full Text] [Related]
16. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637 [TBL] [Abstract][Full Text] [Related]